Hosted by iCAD Inc. (NASDAQ: ICAD)
Watch iCAD’s 2nd annual virtual investor webinar, featuring leading clinical and administrative experts who will share unique perspectives on iCAD’s innovative cancer detection and treatment technologies. Learn how iCAD’s portfolio of deep-learning AI breast health solutions and the Xoft System offer practical solutions that are expertly engineered to enhance clinical workflow, optimize operational efficiency, and improve outcomes for patients.
As we shift from the peak of the pandemic to recovery mode, clinicians are in need of new solutions to navigate today’s challenges. During this virtual event, leading experts from the breast care community shared insights about new innovations in imaging and risk-assessment that may help the clinical community address emerging pandemic challenges, and best practices for how facilities can recuperate from the impact of COVID-19. Learn how the latest technology can help clinicians optimize workflow and patient care during the COVID-19 recovery period and beyond.
Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.
Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.
August 10, 2022
iCAD Reports Financial Results For Second Quarter 2022
August 10, 2022
4:30 pm ET
iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022
May 17, 2022
11:30 am ET
iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference
May 11, 2022
4:30 pm ET
iCAD To Report First Quarter 2022 Financial Results
March 17, 2022
8:00 am ET
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 8, 2022
10:30 am ET
iCAD to Present at the 42nd Annual Cowen Health Care Conference
© iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.